FYB201, a ranibizumab biosimilar, demonstrates equivalent efficacy
- Posted on: Feb 9 2022
- Leave a response
COLUMBUS-AMD is a multicenter, parallel-group, 48-week phase III clinical trial that assessed the equivalence of FYB201, a candidate biosimilar for ranibizumab, with reference ranibizumab.
Source: AAO
Posted in: Uncategorized